ES2127198T3 - Receptores de adhesion para microorganismos patogenos u oportunistas. - Google Patents
Receptores de adhesion para microorganismos patogenos u oportunistas.Info
- Publication number
- ES2127198T3 ES2127198T3 ES91916508T ES91916508T ES2127198T3 ES 2127198 T3 ES2127198 T3 ES 2127198T3 ES 91916508 T ES91916508 T ES 91916508T ES 91916508 T ES91916508 T ES 91916508T ES 2127198 T3 ES2127198 T3 ES 2127198T3
- Authority
- ES
- Spain
- Prior art keywords
- proposals
- receivers
- pathogenic
- galb1
- methods
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000001717 pathogenic effect Effects 0.000 title abstract 3
- 244000005700 microbiome Species 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 4
- 108090000623 proteins and genes Proteins 0.000 abstract 4
- 102000004169 proteins and genes Human genes 0.000 abstract 4
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 abstract 1
- WWUZIQQURGPMPG-BXDGKWANSA-N (2R,3S,4Z)-2-aminooctadec-4-ene-1,3-diol Chemical compound CCCCCCCCCCCCC\C=C/[C@H](O)[C@H](N)CO WWUZIQQURGPMPG-BXDGKWANSA-N 0.000 abstract 1
- 101150016901 ALB1 gene Proteins 0.000 abstract 1
- 101100274294 Arabidopsis thaliana CHLD gene Proteins 0.000 abstract 1
- 101100434646 Mus musculus Alb gene Proteins 0.000 abstract 1
- 229940106189 ceramide Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 1
- 229930195729 fatty acid Natural products 0.000 abstract 1
- 239000000194 fatty acid Substances 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
- C07H15/10—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical containing unsaturated carbon-to-carbon bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
- C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE DESCRIBEN RECEPTORES PARA ORGANISMOS PATOGENOS U OPORTUNISTAS, METODOS PARA LA OBTENCION DE TALES RECEPTORES, METODOS PARA LA UTILIZACION DE ESTOS RECEPTORES PARA DIAGNOSTICO O PROPOSITOS FARMACEUTICOS. EL RECEPTOR COMPRENDE UN COMPUESTO SUSTANCIALMENTE PURO SELECCIONADO DEL GRUPO CONSISTENTE DE GALB1 ALB1 GALB1 GALB1 B1 DROXILATADA, O ESFINGOSINA SATURADA Y R ES H O UN ACIDO DERIVADO GRASO N CERAMIDA. LA INVENCION COMPRENDE ADEMAS PROTEINAS Y POLIPEPTIDOS QUE LIGAN LOS RECEPTORES, PROCESO PARA LA OBTENCION DE TALES PROTEINAS O POLIPEPTIDOS DE FUENTES NATURALES O A TRAVES DE TECNICAS RECOMBINANTES DNA, Y METODOS PARA LA UTILIZACION DE PROTEINAS PURIFICADAS Y POLIPEPTIDOS PARA PROPOSITOS FARMACEUTICOS O DE DIAGNOSTICO, PREFERENTEMENTE EN UNA VACUNA PARA LA ADMINISTRACION A UN ANIMAL O A UN HUESPED HUMANO PARA LA PROTECCION CONTRA MICROORGANISMOS PATOGENOS U OPORTUNISTAS.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US56200290A | 1990-08-02 | 1990-08-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2127198T3 true ES2127198T3 (es) | 1999-04-16 |
Family
ID=24244391
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES91916508T Expired - Lifetime ES2127198T3 (es) | 1990-08-02 | 1991-07-29 | Receptores de adhesion para microorganismos patogenos u oportunistas. |
Country Status (9)
Country | Link |
---|---|
US (1) | US5696000A (es) |
EP (1) | EP0553113B1 (es) |
JP (1) | JPH06501383A (es) |
AT (1) | ATE173827T1 (es) |
CA (1) | CA2095642C (es) |
DE (1) | DE69130536T2 (es) |
DK (1) | DK0553113T3 (es) |
ES (1) | ES2127198T3 (es) |
WO (1) | WO1992002817A1 (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5736533A (en) * | 1995-06-07 | 1998-04-07 | Neose Technologies, Inc. | Bacterial inhibition with an oligosaccharide compound |
EP0869801B1 (en) * | 1995-11-22 | 2004-01-21 | Montana State University | Therapeutic and diagnostic agents for the treatment of microbial infections |
CA2213775C (en) * | 1995-12-27 | 2001-02-27 | Ngk Insulators, Ltd. | Cancer metastasis inhibitor containing a streptococcus agalactiae ia type or ib type surface polysaccharide as a main ingredient |
US6207157B1 (en) * | 1996-04-23 | 2001-03-27 | The United States Of America As Represented By The Department Of Health And Human Services | Conjugate vaccine for nontypeable Haemophilus influenzae |
WO1998037915A1 (en) * | 1997-02-26 | 1998-09-03 | Hsc Research And Development Limited Partnership | Antibiotic-ligand conjugates and methods of use thereof |
AU8967998A (en) * | 1998-02-25 | 1999-09-15 | Hsc Research & Development Limited Partnership | Antibiotic-ligand conjugates and methods of use thereof |
AUPQ275799A0 (en) * | 1999-09-10 | 1999-10-07 | Luminis Pty Limited | Recombinant bacterium expressing an oligosaccharide receptor mimic |
GB0001450D0 (en) | 2000-01-21 | 2000-03-08 | Genpoint As | Cell isolation method |
US6869602B2 (en) * | 2002-02-20 | 2005-03-22 | The United States Of America As Represented By The Secretary Of The Army | Method for treating, preventing, or inhibiting enterotoxigenic Escherichia coli infections with bovine red blood cells |
US20030176326A1 (en) * | 2002-03-15 | 2003-09-18 | Ceramoptec Industries Inc. | Photosensitzers for photodynamic therapy of microbial infections |
DK1629850T4 (da) | 2004-08-24 | 2013-07-01 | Nutricia Nv | Næringssammensætning indeholdende ufordøjelige oligosaccharider |
GB0502095D0 (en) | 2005-02-01 | 2005-03-09 | Chiron Srl | Conjugation of streptococcal capsular saccharides |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4034074A (en) * | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
US4134792A (en) * | 1976-12-06 | 1979-01-16 | Miles Laboratories, Inc. | Specific binding assay with an enzyme modulator as a labeling substance |
US4271140A (en) * | 1978-01-23 | 1981-06-02 | Baxter Travenol Laboratories, Inc. | Method and composition for double receptor, specific binding assays |
US4299916A (en) * | 1979-12-26 | 1981-11-10 | Syva Company | Preferential signal production on a surface in immunoassays |
SE8001748L (sv) * | 1980-03-05 | 1981-09-06 | Kaellenius Gunilla | Kompositioner for terapeutisk eller diagnostisk anvendning jemte forfarande for terapeutik |
WO1981003175A1 (en) * | 1980-05-09 | 1981-11-12 | H Leffler | Carbohydrate derivatives for inhibiting bacterial adherence |
US4376110A (en) * | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US4474892A (en) * | 1983-02-16 | 1984-10-02 | Board Of Trustees Of The Leland Stanford Junior University | Two-site immunoassays using monoclonal antibodies of different classes or subclasses and test kits for performing same |
SE8301609D0 (sv) * | 1983-03-23 | 1983-03-23 | Svenska Sockerfabriks Ab | Forening och komposition for terapeutisk eller diagnostisk anvendning jemte forfarande for terapeutisk behandling |
US4762713A (en) * | 1983-07-05 | 1988-08-09 | The University Of Rochester | Boosting of immunogenic conjugate vaccinations by unconjugated bacterial capsular polymers |
DK219084D0 (da) * | 1984-05-02 | 1984-05-02 | Frederik Carl Peter Lindberg | Antigen |
US4610868A (en) * | 1984-03-20 | 1986-09-09 | The Liposome Company, Inc. | Lipid matrix carriers for use in drug delivery systems |
US4762800A (en) * | 1984-04-26 | 1988-08-09 | Sloan-Kettering Institute For Cancer Research | Monoclonal antibodies to cell surface antigens of human teratocarcinomas |
DK17885D0 (da) * | 1985-01-14 | 1985-01-14 | Karlsson Karl Anders | Antiviralt middel |
US4661345A (en) * | 1985-02-26 | 1987-04-28 | The Rockefeller University | Method for treating pertussis |
US4786592A (en) * | 1986-06-18 | 1988-11-22 | Scripps Clinic And Research Foundation | Neisseria gonorrhoeae lectin useful as a vaccine and diagnostic marker and means for producing this lectin |
IT1235011B (it) * | 1988-07-26 | 1992-06-16 | Fidia Farmaceutici | Sintesi di derivati di glicosfingolipidi ed in particolare di gangliosidi utilizzabili per la preparazione di immunoadsorbenti ed adsorbenti per affinita' impiegabili per la purificazione di anticorpi e di tossine specifiche, e per uso diagnostico |
US5217715A (en) * | 1988-08-01 | 1993-06-08 | The United States Of America As Represented By The Department Of Health And Human Services | Carbohydrate receptor for bacteria and method for use thereof |
US5225330A (en) * | 1988-08-01 | 1993-07-06 | The United States Of America As Represented By The Department Of Health And Human Services | Diagnostic kit and diagnostic method utilizing carbohydrate receptors |
US4969540A (en) * | 1989-09-28 | 1990-11-13 | Allied-Signal Inc. | Center loop anti-rattle spring |
-
1991
- 1991-07-29 JP JP3515061A patent/JPH06501383A/ja active Pending
- 1991-07-29 DK DK91916508T patent/DK0553113T3/da active
- 1991-07-29 AT AT91916508T patent/ATE173827T1/de not_active IP Right Cessation
- 1991-07-29 EP EP91916508A patent/EP0553113B1/en not_active Expired - Lifetime
- 1991-07-29 CA CA002095642A patent/CA2095642C/en not_active Expired - Fee Related
- 1991-07-29 WO PCT/US1991/005179 patent/WO1992002817A1/en active IP Right Grant
- 1991-07-29 ES ES91916508T patent/ES2127198T3/es not_active Expired - Lifetime
- 1991-07-29 DE DE69130536T patent/DE69130536T2/de not_active Expired - Fee Related
-
1994
- 1994-07-18 US US08/275,702 patent/US5696000A/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US5696000A (en) | 1997-12-09 |
CA2095642C (en) | 1999-12-14 |
DK0553113T3 (da) | 1999-08-09 |
EP0553113A1 (en) | 1993-08-04 |
ATE173827T1 (de) | 1998-12-15 |
WO1992002817A1 (en) | 1992-02-20 |
DE69130536D1 (de) | 1999-01-07 |
EP0553113B1 (en) | 1998-11-25 |
DE69130536T2 (de) | 1999-04-22 |
EP0553113A4 (es) | 1994-03-30 |
JPH06501383A (ja) | 1994-02-17 |
CA2095642A1 (en) | 1992-02-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2127198T3 (es) | Receptores de adhesion para microorganismos patogenos u oportunistas. | |
ES2167717T3 (es) | Nuevos aminoacidos ciclicos sustituidos como agentes farmaceuticos. | |
ES2058083T3 (es) | Anticuerpos monoclonales contra el factor humano de la necrosis tumoral (tnf) y su empleo. | |
ES2171224T3 (es) | Nuevos peptidos opioides. | |
ES2057553T3 (es) | Sitios hidrofobicos de fijacion para peptidos de adherencia. | |
ES2130265T3 (es) | Region de union al receptor de la toxina difterica. | |
ES2174859T3 (es) | Composiciones terapeuticas que contienen anticuerpos monoclonales especificos para un receptor humano del factor de crecimiento epidermico. | |
BR8707672A (pt) | Pirazolinas inseticidas | |
AR003423A1 (es) | Anticuerpos monoclonales humanos de alta afinidad especificos de la proteina- f del rsv, celulas eucarioticas transfectadas; secuencia de adn y vector de expresion que lo codifican; metodo que utiliza los anticuerpos; una composicion farmaceutica que los contiene; metodo para detectar rsv y un kit de ensayo. | |
ES2148799T3 (es) | Anticuerpos monoclonales neutralizantes contra virus sincitial respiratorio. | |
EA199800946A1 (ru) | Концентрированный препарат антител | |
ES2149772T3 (es) | Receptores humanos pf4a y su utilizacion. | |
ES2153367T3 (es) | Derivados de clorofila y de bacterioclorofila, su preparacion y composiciones farmaceuticas que los contienen. | |
PT73161A (fr) | Procede pour la preparation de derives de n-(vynblastinoyl-23) aux amino-acids et peptides et son application terapeutique | |
ES2104702T3 (es) | Metodo y composicion para el tratamiento de la trombosis. | |
ES2167592T3 (es) | Preparaciones medicamentosas que contienen un enantiomero de bromuro de ipratropio con duracion de la accion prolongada. | |
ES2134187T3 (es) | Preparaciones farmaceuticas. | |
BG95786A (bg) | Препарат за контролирано освобождаване на активни вещества за преживни животни | |
ES2102347T3 (es) | Metodos y composiciones para la utilizacion de polipeptidos env y anticuerpos anti-env de hiv. | |
BR9810907A (pt) | Anticorpos monoclonais e policlonais, peptìdeo suscetìvel de gerar um anticorpo, agente imunogênico, sequência de nucleotìdeos, composição farmacêutica, uso de pelo menos um anticorpo, kit de diagnóstico, e, processo para preparar um agente imunogênico | |
EA199700253A1 (ru) | Производные нодулиспоровой кислоты | |
ES2031834T3 (es) | Benzazepinas fusionadas. | |
AR246310A1 (es) | Procedimiento para la preparacion de la cadena alfa- del receptor de la interleucina 5 humana, o partes del mismo, secuencia del adn, vector y celula hospedante. | |
ES2061521T3 (es) | Proteinas con actividad glutation-s-transferasa, secuencias de adn, anticuerpos, poxvirus y medicamentos para la prevencion de la equistosomiasis. | |
MX9302327A (es) | Aminoacidos ciclicos novedosos y derivados de los mismos. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 553113 Country of ref document: ES |